View by type:
Other(716)
Evaluation of Gavi Independent Review
2023 evaluation of Gavi's Independent Review Committee: its design, execution, and results.
A preliminary assessment of COVAX’s impact in lower-income countries
Approximately 90% of COVAX-delivered COVID-19 doses have gone to lower-income economies. This represents the fastest and most complex global deployment of vaccines ever. But in terms of achieving equitable access during this pandemic, how…
COVAX Facility and COVAX Advance Market Commitment (AMC) Formative Review and Baseline Study
Gavi, the Vaccine Alliance appointed Itad to conduct an evaluability assessment and evaluation design study, and a baseline study of the COVAX Facility and COVAX Advance Market Commitment (AMC).
Evaluation of Gavi’s initial response to COVID-19
Gavi, the Vaccine Alliance appointed Euro Health Group (EHG) to conduct an evaluation of Gavi’s initial response to COVID-19.
Learning and Performance Management (LPM)
Improving health worker performance and health outcomes.
Vaccine Investment Strategy 2024
Gavi’s Vaccine Investment Strategy (VIS) is the prioritisation process for inclusion of new and underused vaccines that will be made available to countries through our vaccine support programmes.
Malaria vaccine market shaping roadmap
The development of the world’s first safe and effective malaria vaccine is a truly historic breakthrough. However, to harness its potential to help save many of the more than 600,000 lives claimed by the disease every year, much work still needs…